Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Cash & Equivalents for 6 consecutive years, with $111.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 54.98% year-over-year to $111.0 million, compared with a TTM value of $111.0 million through Dec 2025, up 54.98%, and an annual FY2025 reading of $111.0 million, up 54.98% over the prior year.
  • Cash & Equivalents was $111.0 million for Q4 2025 at Xeris Biopharma Holdings, up from $91.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $122.0 million in Q4 2022 and bottomed at $46.1 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $73.0 million, with a median of $65.0 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents surged 81.31% in 2022, then tumbled 51.57% in 2023.
  • Year by year, Cash & Equivalents stood at $67.3 million in 2021, then soared by 81.31% to $122.0 million in 2022, then tumbled by 44.7% to $67.4 million in 2023, then grew by 6.19% to $71.6 million in 2024, then soared by 54.98% to $111.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for XERS at $111.0 million in Q4 2025, $91.6 million in Q3 2025, and $59.3 million in Q2 2025.